Iron overload (Formulary)

Important: Formulation and dosage details

Formulation:

Tablets 90mg, 180mg, 360mg (s)

Dosage:

As per SMC1246/17:

• Treatment of chronic iron overload due to frequent blood transfusions (≥7mL/kg/month
  of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.
• Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:
  • in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7mL/kg/month of packed red blood cells) aged 2
    to 5 years,
  • in adult and paediatric patients with beta thalassaemia major with iron overload
    due to infrequent blood transfusions (<7mL/kg/month of packed red blood cells)
    aged 2 years and older,
  • in adult and paediatric patients with other anaemias aged 2 years and older.

SMC restriction: deferasirox film-coated tablets are restricted to use as for the SMC advice issued for deferasirox dispersible tablets (347/07: treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate, in adult and paediatric patients aged 2 years and older with rare acquired or inherited anaemias.  The current advice relates only to use in the myelodysplastic syndrome (MDS) population.  SMC restriction: use in patients with MDS with an International Prognostic Scoring System
(IPSS) score of low or intermediate -1 risk.)

Important: Formulation and dosage details

Formulation:

Injection 500mg, 2 grams (s)